Health Canada approves first RSV vaccine for adults age 60 and over - The Canadian Press https://apple.news/AFCmGdpxtR_mNw3CTxn6XGg
#HealthCanada has approved the first vaccine for respiratory syncytial virus (#RSV) for adults age 60 and over.
..older people are much more likely to become severely ill and require #hospitalization…a randomized clinical trial showed the vaccine, called #Arexvy, was 82 per cent effective at preventing lower respiratory tract disease caused by RSV compared to.. placebo.

New vaccine for disease that kills 8,000 over 60s in UK annually - respiratory syncytial virus, #RSV, vaccine for older adults.
Medicines & Healthcare products Regulatory Agency, #MHRA, approved GSK vaccine, #Arexvy, for use among older adults. @Cambslive
https://www.cambridge-news.co.uk/news/uk-world-news/new-vaccine-killer-disease-rsv-27289971?utm_source=twitter.com&utm_medium=social&utm_campaign=sharebar

#RSV #vaccine for older #adults approved by UK medicines regulator

📌 #Arexvy could help NHS deal with virus that causes about 8,000 deaths among older people in UK each year

📌 A study of 24,966 older adults published in the New England Journal of Medicine in February suggested vaccine efficacy against lower respiratory tract disease was 82.6%, while efficacy against serious disease was 94.1%.

https://www.theguardian.com/society/2023/jul/10/rsv-vaccine-respiratory-syncytial-virus-older-adults-approved-uk-medicines-regulator

Virus respiratorio sinciziale, l'UE 🇪🇺 autorizza il vaccino per gli over 60
#RSV

📌. Dopo il sì degli USA, arriva quello dell'Europa: #Arexvy è il primo vaccino che protegge gli adulti contro la malattia del tratto respiratorio inferiore provocata dal virus

https://www.repubblica.it/salute/2023/06/06/news/virus_respiratorio_sinciziale_rsv_vaccini-403418728/?rss

The New #Vaccine Your Patients May Not Want

📌 The 🇺🇸 Food and Drug Administration (FDA) recently approved #Arexvy, a vaccine against respiratory syncytial virus (RSV) for adults aged 60 years or older.

📌Clinicians tend to think of RSV as a serious disease in young children — which it is — but data suggest that in 2019, RSV infection led to more than 100,000 hospitalizations and 7700 deaths in older adults in the United States.

https://www.medscape.com/viewarticle/991993?src=rss

🇺🇸 drug regulator approves world's first #RSV #vaccine

📌 The 🇺🇸 FDA has approved a vaccine against respiratory syncytial virus (RSV) - an illness that kills thousands of Americans/year.

📌 The vaccine still needs approval from the US CDC before it can be rolled out to the public.

📌 Officials say the vaccine, named #Arexvy by the manufacturer GSK, is a major breakthrough that will save many lives.

📌It could be available to people over 60 within months, officials say.

https://www.bbc.com/news/world-us-canada-65477747?at_medium=RSS&at_campaign=KARANGA

US FDA Approves GSK’s AREXVY, the World’s First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults

GSK plc (LSE/NYSE: GSK) today announced that the #FDA has approved #AREXVY (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (#RSV) in individuals 60 years of age and older.

#Healthcare #Seniors
https://apnews.com/54ab6336198c4fe68d5988f6edb1a1d6